Compare Illumina, Inc. (ILMN) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Illumina, Inc. trades at $180.13 (market cap $27.94B), while YieldMax Universe Fund of Option Income ETFs trades at $7.62. The key difference: Illumina, Inc. is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| ILMN | YMAX | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $194.33 | $14.00 |
52-Week Low | $91.00 | $7.51 |
Enterprise Value | $29.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
YMAX trades at $7.52 with no recent price movement. Technical indicators show a bearish trend, with moving averages signaling sell pressure and oscillators neutral. The fund generates weekly dividend income, though recent news highlights concerns over fee structures impacting payouts. Support and resistance are tightly clustered around $7 and $8, indicating limited near-term price range.
Outlook remains cautious due to bearish technicals and cost structure headwinds. The high-yield strategy offers income but faces erosion from layered fees. Key risks include dependency on market volatility for strategy success and competitive pressures in the ETF space. Investors should weigh yield against potential capital depreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
